once candidates were identified, all recruitment efforts could be directly targeted to specific patients as opposed to advertising to a large, undefined population or relying on physician referral. This resulted in improved patient response rates, which could conceivably be improved further with the creation of more targeted recruitment materials developed by patient demographic profiles generated from EMR data.
Objectives: Longitudinal Patients Database (LPD) is a primary care database of anonymized electronic medical records (EMR) from about 4 % of the French population. Diagnosis and prescription data are routinely collected from proprietary practice management software used by physicians (primary care and specialists) to maintain EMR of their patients. Although LPD has been extensively validated by numerous publications and its use by French National Health Authorities, this is the first time that its representativeness and validity is systematically examined. MethOds: The distribution of several variables were analyzed and compared to available literature. Part of these variables refers to physician's practices participating to the database while others refer to patients in these practices. Data about prevalence, treatments, and patients profile were retrieved from published French Health Authorities studies based on LPD data and compared to other published sources. Results: The sampling methods for the physician's selection practices were shown to provide a good representativeness of the physician panel. Analyze of the patients population showed that LPD included all the subsets of the French general population, although pediatrics were underrepresented. Prevalences of several illnesses (diabetes, asthma, atrial fibrillation, aortic aneurism), treatments (dyslipidemia, diabetes), patients' profiles (dyslipidemia, atrial fibrillation, venous disease) were in agreement to those encountered in literature. However, smoking status, hospitalizations, referral to specialists were only partially reported and no information was available about sociodemographic status or death of patients. The availability of missing information through the use of questionnaires/pop up screens for physicians and patients, and the linkage of the EMR database to a claims database (HEAD) is also documented. cOnclusiOns: We found no indications of lack of representativeness or validity of the LPD. While presenting some flaws associated with its naturalistic nature, LPD is a good support for pharmacoepidemiological and pharmacoeconomics studies. Objectives: Lack of a coordinated primary care system is forcing individuals to seek emergency departments (EDs) as gateway into the health system. As volumes increase and cases become more complex, combined with inadequate downstream capacity lead to boarding, bottlenecks and wait times. The goal was to review benefits of Radio Frequency identification (RFID) demonstrated in the literature in the ED. MethOds: Article searches were conducted and they were categorized based on benefits in three areas: patients, staff, assets. Results: Evidence of use of RFID in ED went as far back as 2006 with both domestic and international applications mostly using active technology. Majority of the articles demonstrated reducing wait times in the ED. One of the articles in turn demonstrated impact on patient satisfaction. Reduction in wait times were demonstrated when admitting patients into ICU from the emergency setting. In case of staff, use of RFID demonstrated increased satisfaction in a pediatric emergency setting. Evidence also exists in better tracking of assets and equipment in the ED. Very little evidence of use of RFID in simulation and analytical models exist. Most of the studies were retrospective in nature. Wait times and asset tracking are tangible benefits with direct impact on return-on-investment. cOnclusiOns: RFID has been used is various settings in healthcare and quality benefits have been demonstrated. Lesser evidence of RFID use in the ED exists. RFID benefits have primarily been demonstrated with regard to wait times and asset tracking and management. Patient and staff satisfaction are more intangible benefits. As EDs start to reap benefits with wait times, use in simulation and advanced analytical models could potentially inform workload, team configuration and team dynamics studies. As healthcare moves into the era of big data, live streaming RFID data can be tapped for real-time decision making. Objectives: To evaluate the most common reasons provided by peer-reviewed journals to reject manuscripts describing data derived from real-world or healtheconomic (RW/HE) studies. MethOds: Our company project administration records from the last 10 years were reviewed for manuscripts describing HE studies, RW/observational studies (including retrospective database analyses), and patient or disease registries. Reasons for rejection were collected and stratified into "categories". If more than one reason was provided by the journal, then all reasons were counted. Our analysis was based on industry-sponsored manuscripts for which a complete submission history was available. Results: Rejection letters were collected for 78 manuscripts. Of these, 12 did not specify a reason for rejection. The remaining records revealed a total of 100 rejection counts. The most common reasons were 'priority rating not high enough' (33%), 'concerns about the methodology' (18%), and 'information not sufficiently novel' (15%). Other reasons for rejection included 'topic not appropriate for the journal' (7%), 'manuscript is biased/conclusions are too strong' (5%), 'industry involvement not sufficiently disclosed' (2%), and referral to a sister journal instead (2%). cOnclusiOns: These common reasons for rejection could provide authors with some guidance on which factors are particularly important to focus on during the development of a RW/HE manuscript to help improve the chances of acceptance by peer-reviewed journals.
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PRM46 WHy PeeR-RevieW JoURnaLs ReJeCt ReaL-WoRLd and HeaLtH-eConoMiC PaPeRs
PRM47 UtiLizing eLeCtRoniC MediCaL ReCoRd netWoRks foR identifying Patients foR CLiniCaL tRiaL ReCRUitMent
Spencer J. , Wilson A. , Bailey N. , Longson M. S. , Kamauu A. Anolinx, Murray, UT, USA Objectives: Much of the increase in health-care expenses in the U.S. can be traced to the development of new drug therapies; with the average discovery and development process costing over $1.4 billion per drug. This motivates the need to reduce drug costs through more efficient drug development and testing, specifically, by streamlining clinical trials. The current study aims to implement and evaluate a process, using a data driven approach, to recruit patients for a clinical trial for an asthma treatment. Our hypothesis is that recruitment could be improved and accelerated with the support of an EMR network to identify patients. MethOds: All trial protocol eligibility criteria were reviewed in the context of EMR data availability, as well as protocol-specific procedures. We then queried our EMR network to identify sites with high patient concentrations. Four sites were recommended to the team by partners in this network and selected, with one site opting not to participate in the study after being selected. Results: EMR queries identified over 300 potentially eligible patients at three different sites. Of identified patients who were contacted, and for whom information was available, 84% responded to outreach efforts, which represents a very substantial increase over the 10% that is typical in the industry. Among respondents, enrollment rates ranged from 14% to 40%. cOnclusiOns: For all participating sites, querying EHR data proved to be an effective means of identifying eligible patients. Furthermore,
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CHoiCe of distRibUtionaL assUMPtions in Meta-anaLysis foR tHe evaLUation of sURRogate endPoints Spata E. , Abrams K. R. , Thompson J. , Bujkiewicz S.
University of Leicester, Leicester, UK
Objectives: In health technology assessment meta-analysis is used to combine evidence from a number of studies to inform the decision-making process. When evaluating new health technologies at early stages of their development, treatment effects on short-term surrogate endpoints may be used to predict the effect on the final outcome that otherwise requires long follow-up time. Meta-analysis of multiple outcomes which takes into account the correlations between them is particularly suitable for modelling surrogate endpoints. The aim of this study was to investigate the choice of distributional assumptions when developing metaanalytic methods for evaluation of surrogate endpoints. MethOds: Two bivariate meta-analytical models are applied to a case study in chronic myeloid leukaemia where overall survival (OS) proportion, is the final outcome and complete cytogenetic response (CCYR) rate at 12 months is a surrogate endpoint. A normal model on log relative risk scale for both outcomes is applied to evaluate CCYR as a surrogate endpoint for OS. This model is then extended by relaxing the assumption of normality by the use of binomial distributions for both outcomes. Results: The effect on CCYR was a significant predictor of the effect on OS. Both models gave similar results for the effect of CCYR on OS. However, the heterogeneity parameter was larger in the binomial model (τ 2= 0.09 with 95% CrI; 0.0 to 0.52) compared to normal case (τ 2= 0.07 with 95% CrI; 0.0 to 0.39). cOnclusiOns: The results of both models were similar for this case study. However, the choice of distributional assumption can lead to different estimates of the effect on the final outcome in other disease areas when the normality assumption is not suitable and consequently this can impact on HTA decisions.
PRM54 UniveRsaL CLoPidogReL veRsUs CyP2C19-gUided antiPLateLet tHeRaPy in Patients WitH aCUte CoRonaRy syndRoMe -a Cost-effeCtiveness anaLysis
Jiang M. , You J.
The Chinese University of Hong Kong, Shatin, Hong Kong
Objectives: The gene of CYP2C19 is highly polymorphic and influences the metabolism of clopidogrel. Using CYP2C19 genotype data, patients at risk of inadequate antiplatelet effect with clopidogrel could be identified and treated with a new antiplatelet agent (prasugrel or ticagrelor). This study aimed to evaluate the costeffectiveness of genotype-guided therapy versus universal clopidogrel treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). MethOds: A lifelong Markov model, from the perspective of healthcare provider, was designed to simulate two treatment strategies: universal generic clopidogrel and genotype-guided therapy (generic clopidogrel for patients without CYP2C19 loss-of-function (LOF) allele and new oral antiplatelet drug (prasugrel or ticagrelor) for patients with at least one LOF allele). Model inputs were derived from published meta-analysis and clinical trials. Direct medical costs and qualityadjusted life-year (QALY) gained were the primary model outcomes. One-way and probabilistic sensitivity analyses were performed. Results: Base-case analyses illustrated that universal clopidogrel strategy cost $76,335 with 7.919 QALYs, while genotype-guided therapy cost $73,131 with 8.068 QALYs. With a threshold of willingness-to-pay of $50,000 per QALY, genotype-guided therapy remained the preferred strategy throughout variations of all model inputs in one-way sensitivity analysis with no threshold value identified. The most influential factor was the probability of ischemic heart disease (IHD) state turned to death, followed by the possibility of post myocardial infarction state turned to death, cost of PCI and utility of IHD. In probabilistic sensitivity analysis, genotype-guided therapy was dominant with costsaving $3472 (95% confidence interval (CI): 3448-3496) and a gain of 0.2425 QALY (95% CI: 0.2421-0.2429) compared with universal generic clopidogrel. cOnclusiOns: Genotype-guided therapy appears to be the preferred strategy when comparing to universal generic clopidogrel treatment for patients with ACS undergoing PCI. Objectives: We presented an approach to jointly estimate Markov chain transition probabilities using survival models and constrained optimization to avoid the negative probabilities resulting from separate estimations via a case study on diabetes and mortality. MethOds: We used data from the National Health Interview Survey, 1997 Survey, -2006 , and built a three-state (well, diabetes, and death) Markov model with a cycle length of one year. In this model, the transition probability from the diabetes state to the well state was assumed to be zero. The other probabilities in the transition matrix were jointly estimated based on survival models and constrained optimization. First, the probability of developing diabetes and that of death were modeled using an exponential survival function, controlling for body mass index (BMI), age, and gender. Second, the nonlinear least squares approximation method was used to estimate the transition probability from well to well based on the data. Last, we simultaneously maximized the combined log-likelihood functions derived from the survival functions under the constraints that the sum of the probabilities of all possibilities must add up to one. Results: Using individuals aged 50-59 as an example, the transition probability from well to diabetes was 0.00087 for normal-weight women and 0.00081 for normal-weight men, 0.0015 for overweight women and 0.0014 for overweight men, and 0.0034 for obese women pleted the questionnaire online. A qualitative analysis of the data, using a combination of deductive (based on literature) and inductive (based on expert's opinion) approaches were performed using NVIVOv10 Software. Results: A hierarchical structure of 100 nodes was designed around 2 main themes: LAIT and chronic graftrejection. According to expert interviews, LAIT is a common issue that can have significant health consequences. The main drivers of adherence were the number of pills and incidence of adverse events. The main consequences identified by the experts were antibody mediated graft-rejection and decreased graft survival. CHR was identified as the second most common cause of graft rejection between 2-3 years post-transplant, behind death with a functioning graft. LAIT could cause up to 50% of CHR. There is no consensus on treating CHR, but therapies include intravenous immunoglobulins, rituximab and plasmapheresis. Other health resources used include: at least one diagnostic renal biopsy, 2-fold increase in follow-up clinical visits, a higher risk of hospitalization due to complications (infections, heart-failure and anaemia) and preparation for return to dialysis. Most CHR episodes resulted in graft loss and return to dialysis with high associated costs. cOnclusiOns: Poor adherence is considered a preventable but frequent cause of CHR and graft loss. Treatment simplification and education could improve adherence and burden of disease for KT patients. Patient subgroup Markov transition probability (MTP) matrices were implemented in the MCm, with assumptions regarding unpublished information on post-initial cycle state transitions. These assumptions involved subgroup treatment effects, patient decision discontinuation, and treatment stopping rules. The overall patient population (OPP) MTP matrices generated by the MCm were loaded into the Markov model to assess the validity of the assumptions. Results: Incremental costs and quality-adjusted life-years (QALYs) between intervention with onabotulinumtoxinA and placebo were produced. Differences between published and replicated Markov model incremental cost and QALY results were small for the base case (0.0%, -1.1%) and selected sensitivity analyses (maximum differences [1.9%, -1.9%]). Base case differences between published and the replicated Markov model (using MCm-derived OPP MTP matrices) incremental cost and QALY results were larger but acceptable (5.2%, 11.7%). This reflects the assumptions involved with the approximation of the patient subgroup MTP matrices. cOnclusiOns: The study demonstrates how a published model can be replicated and adapted for early phase CEA investigations, allowing for modeling of OPPs, treatment effects, treatment discontinuation, etc. that differ from the published model. Objectives: To conduct pharmacoeconomic analyses, both cost and effectiveness data are required. Randomized controlled trials (RCTs) are often used as a source of efficacy data. As RCTs are often of short duration, efficacy data need to be extrapolated beyond the trial follow-up period to be fit for use in model-based pharmacoeconomic evaluations. However, RCTs usually report effectiveness data in terms of Kaplan-Meier (KM) estimates. As a result, researchers need to reconstruct individual patient data (IPD) from published KM curves of trials' treatment arms to estimate their long-term effects. This study aims to reconstruct the survival benefits of regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial. MethOds: An algorithm developed by Guyot and colleagues was adopted to reconstruct IPD using R statistical package, based on the overall survival KM curves of the CORRECT trial. The reconstruction of IPD included the following steps: 1) extraction of coordinates from published KM curves, 2) data accuracy check, 3) creation of a second dataset, and application of the algorithm. The results of the original trial were compared to the reconstructed data using graphical and quantitative methods, for validation purposes. Results: Based on the IPD reconstruction, 162 and 88 events occurred in the regorafenib and placebo groups respectively. The median overall survival time in the regorafenib arm was 6.5 months (95% CI 5. 83, 8.43 ) which is about the same as the original trial (6.4 months). In the placebo group, the median overall survival for the reconstruction data was 5.09 months (95% CI 4.30, 6.81) compared to the trial median survival of 5.0 months. cOnclusiOns: The results of this study can be utilized to estimate transition probabilities for model-based pharmacoeconomic evaluations in the absence of individual patient data (IPD).
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